Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53 MEDIA & INVESTOR RE…

Business

Welcome to /f/business! This blurb is dedicated to business news and discussions. Whether you're an entrepreneur, investor, or simply interested in the latest developments in the business world, you've come to the right place. Share and discuss market trends, financial news, industry insights, startups, and more.

Our basic rules ensure a constructive and respectful community:

Be respectful: Maintain a civil tone, avoid personal attacks, and refrain from using derogatory language.
Stay on topic: Keep posts and comments relevant to business news and related topics.
Provide reliable sources: Cite credible sources whenever possible to foster informed discussions.
Avoid self-promotion: Contribute valuable insights rather than excessively promoting yourself or your business.
No financial or investment advice: Seek professional advice and avoid considering shared information as expert advice.

Use the upvote and downvote buttons to highlight quality content and maintain engagement. Enjoy your time here and contribute to the ever-evolving world of business news!

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia - Novartis

Comments